Document is current

Article History

Accepted: 21 April 2022

First Online: 21 May 2022

Declarations

:

: No funding was received for the preparation of this article.

: <i>Egídio Freitas:</i> consulting fees from Leo Pharma. <i>Melinda Gooderham:</i> Honoraria, grants, and/or research funding as a speaker, investigator, advisory board member, data safety monitoring board member, and/or consultant for AbbVie, Amgen, Akros, Arcutis, Aslan, Bausch/Valeant, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Dermira, Dermavant, Eli Lilly, Galderma, Janssen, Kyowa Hakko Kirin Pharma, LEO Pharma, MedImmune, Merck & Co., Novartis, Pfizer, Regeneron, Roche Laboratories, Sanofi Genzyme, Sun Pharma, and UCB. <i>Tiago Torres:</i> research grants and/or consulting fees from AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Samsung-Bioepis, Sandoz, Sanofi, and Viatris.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: EF, MG, and TT had the idea for the article, performed the literature search and data analysis, and drafted and critically revised the work.